Magazine
Becoming a Psychedelic Researcher: Alan Kooi Davis
Why researchers like Alan Kooi Davis — the newest addition to the Johns Hopkins psychedelic research team — decide to devote their careers to studying psychedelics.
Science
Magazine
We talked with a researcher using psilocybin for cocaine addiction in Alabama
I came to a working hypothesis: at the center of the mystical experience is awe, wherein one is in the presence of something so great, so large, that it requires they completely reorder their mental structures – completely change the way they view reality.
Magazine
LSD Cured My Eating Disorder
As a teenager, I was taking ten milligrams of Ritalin daily. Later, I grew to love the way these pills made it easier for me not to eat.
Magazine
We now call ‘bad trips’ ‘challenging experiences’. Here’s why that’s misguided.
Renaming adverse effects of psychedelic drugs as “challenging experiences” minimizes, almost trivializes, their negative effects.
Magazine
Psychedelics and the Full-Fluency Phenomenon
I first discovered the potential psychedelics have for treating stuttering during an experience with psilocybin mushrooms.
Magazine
Is Ibogaine the Cure for Opioid Addiction? It’s Not That Simple. | Part 11
The Ibogaine Conversation Conclusion | The goal of this conversation was to provide a platform for a diverse range of perspectives on a single topic. Not everyone agrees, and that’s the point.
Magazine
Ibogaine Treatment Comes with Risks. We Had a Discussion About Safety with Medical Providers. | Part 10
The Ibogaine Conversation Part 10 | Unlike other psychedelic drugs, ibogaine is known to be potentially cardiotoxic. There are a number of fatalities associated with its use, and anyone considering working with it should be aware of the risks.
Magazine
How Safe is Ibogaine? We Asked Clare Wilkins Who Has Facilitated Over 700 Treatments | Part 9
The Ibogaine Conversation Part 9 | Using ibogaine can be fatal if proper safety precautions aren’t taken.
Magazine
How Not to Do Ibogaine 101 with Juliana Mulligan | Part 8
The Ibogaine Conversation Part 8 | This is not a do-it-at-home type thing.
Magazine
Former Underground Provider, Dimitri Mugianis, on the Regulation of Ibogaine | Part 7
The Ibogaine Conversation Part 7 | “Prescription is not about accessibility, by definition it’s about restriction. Unless we start to use psychedelics as a way to tear apart these structures and build new ones in their place, then I think it’s all a revolving door.”
Magazine
Patrick Kroupa, hacker and ex-heroin ‘junkie’, on microdosing and the medicalization of ibogaine | Part 6
The Ibogaine Conversation Part 6 | My experience with heroin went from age 14 up to age 30, and taking ibogaine was as close to a miracle as I have ever experienced in my life.
Magazine
Talking Ibogaine Research for Opioid Addiction with Thomas Kingsley Brown | Part 5
The Ibogaine Conversation Part 5 | Thomas Kingsley Brown, PhD, studied the long-term outcomes of people who received ibogaine for the treatment of opioid addiction. We talked about the results.